Prot #MRG106-11-101: A Phase 1 Dose-Ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 following Local Intratumoral and Subcutaneous Injection in Patients with Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF) Su